Cancer metastasis is a primary cause of
cancer death.
Ovatodiolide, a bioactive
cembrane-type
diterpenoid isolated from Anisomeles indica (L.) Kuntze (Labiatae), has been shown to inhibit the growth and proliferation of
cancer cells. However, the anti-metastatic effects of
ovatodiolide on highly metastatic human
breast cancer MDA-MB-231 cells remain unclear. In this study, we first noted that
ovatodiolide inhibited MDA-MB-231 cell migration and invasion by wound-healing assay and Boyden chamber assay. Western blot,
gelatin zymography and reversed transcription-PCR analysis showed that
ovatodiolide significantly and selectively suppressed the expression, activation, and
mRNA of
matrix metalloproteinase-9 (MMP-9) in a concentration-dependent manner.
Ovatodiolide significantly decreased the nuclear level of
nuclear factor kappaB (NF-κB), increased inhibitor of kappaBα (IκBα) through preventing phosphorylation of upstream signal IκB
kinase (IKK). Pretreatment with a specific NF-κB inhibitor (
PDTC) and an IκB
protease inhibitor (
TPCK) also reduced MMP-9 activity, cell migration and cell invasion. Moreover,
ovatodiolide can suppress activation of
c-Jun N-terminal kinase,
p38 mitogen-activated protein kinase,
phosphatidylinositol 3-kinase and Akt, while it did not affect phosphorylation of extracellular signal regulating
kinases (ERK)1/2. Additionally, the treatment of inhibitors specific for PI3K (
wortmannin), JNK (
SP600125) or
p38 MAPK (
SB203580) to MDA-MB-231 cells could result in a reduced activation of MMP-9, concomitantly with a marked inhibition on cell migration and invasion. Taken together, these results demonstrate that
ovatodiolide inhibits the metastatic ability of MDA-MB-231 cells by reducing MMP-9 activity through suppressing JNK,
p38 MAPK and PI3K/Akt signaling pathways and inhibiting NF-κB activity. These results are the first to reveal the function of
ovatodiolide in
tumor metastasis and its underlying molecular mechanism, thus suggesting
ovatodiolide to be a promising antimetastatic agent.